Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
QL Biopharm Raises Series B Funding for Protein Drug Development
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...
Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...
HKUST and PhIRDA Sign MoU to Establish Innovation Centers
The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...
China Releases Blue Book on Medical Insurance Fund Supervision
The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...
NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...